Anebulo Pharmaceuticals (ANEB) Total Liabilities (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Total Liabilities of $1.5 million for Q4 2025, up 69.05% year-over-year from $878799.0 in Q4 2024, and up 54.14% quarter-over-quarter from $963821.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Total Liabilities (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Total Liabilities for 6 consecutive years, with $1.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities rose 69.05% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $1.5 million (up 69.05% YoY), while the FY2025 annual figure was $487688.0, up 87.15% from the prior year.
- Total Liabilities improved to $1.5 million in Q4 2025 per ANEB's latest filing, from $963821.0 in the prior quarter.
- Across five years, Total Liabilities topped out at $10.8 million in Q1 2021 and bottomed at $49944.0 in Q4 2021.
- Historically, Total Liabilities has averaged $1.2 million across 5 years, with a median of $707369.5 in 2022.
- On a YoY basis, Total Liabilities climbed as much as 2647.88% in 2022 and fell as far as 99.2% in 2022.
- Anebulo Pharmaceuticals' Total Liabilities stood at $49944.0 in 2021, then surged by 2647.88% to $1.4 million in 2022, then slipped by 26.15% to $1.0 million in 2023, then decreased by 13.3% to $878799.0 in 2024, then soared by 69.05% to $1.5 million in 2025.
- Business Quant data shows ANEB's Total Liabilities at $1.5 million in Q4 2025, $963821.0 in Q3 2025, and $487688.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 10.03 Bn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 1.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.49 Mn |
| Sep 30, 2025 | 963,821.00 |
| Jun 30, 2025 | 487,688.00 |
| Mar 31, 2025 | 546,032.00 |
| Dec 31, 2024 | 878,799.00 |
| Sep 30, 2024 | 569,225.00 |
| Jun 30, 2024 | 260,583.00 |
| Mar 31, 2024 | 1.01 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 716,560.00 |
| Jun 30, 2023 | 1.07 Mn |
| Mar 31, 2023 | 1.49 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 698,179.00 |
| Jun 30, 2022 | 512,531.00 |
| Mar 31, 2022 | 85,777.00 |
| Dec 31, 2021 | 49,944.00 |
| Sep 30, 2021 | 607,706.00 |
| Jun 30, 2021 | 241,633.00 |
| Mar 31, 2021 | 10.75 Mn |